Results 121 to 130 of about 1,361 (136)
Some of the next articles are maybe not open access.
British Journal of Clinical Pharmacology
Aims Adavosertib, a WEE1 inhibitor, has been studied for safety and efficacy as monotherapy and in combination therapy. The phase 2b ADAGIO trial (NCT04590248) evaluated adavosertib monotherapy for uterine serous carcinoma with a recommended dose of 300 mg administered on days 1–5 and 8–12 of a 21‐day cycle ...
Diansong Zhou +2 more
exaly +3 more sources
Aims Adavosertib, a WEE1 inhibitor, has been studied for safety and efficacy as monotherapy and in combination therapy. The phase 2b ADAGIO trial (NCT04590248) evaluated adavosertib monotherapy for uterine serous carcinoma with a recommended dose of 300 mg administered on days 1–5 and 8–12 of a 21‐day cycle ...
Diansong Zhou +2 more
exaly +3 more sources
Adavosertib and beyond: Biomarkers, drug combination and toxicity of WEE1 inhibitors
Critical Reviews in Oncology/HematologyWEE1 kinase is renowned as an S-G2 checkpoint inhibitor activated by ATR-CHK1 in response to replication stress. WEE1 inhibition enhances replication stress and effectively circumvents checkpoints into mitosis, which triggers significant genetic impairs and culminates in cell death.
Chi, Zhang +4 more
exaly +3 more sources
The FASEB Journal, 2022
Current treatment for leukemia focuses on DNA damaging treatments (DNAdt), including chemo (cytarabine, vincristine, doxorubicin, etc.) and/or radiotherapy. However, in both adult and pediatric patients with Acute Lymphoblastic Leukemia (ALL), value of these treatments are limited by development of chemoresistance.
Gabriel O. Rodríguez‐Vázquez +4 more
openaire +1 more source
Current treatment for leukemia focuses on DNA damaging treatments (DNAdt), including chemo (cytarabine, vincristine, doxorubicin, etc.) and/or radiotherapy. However, in both adult and pediatric patients with Acute Lymphoblastic Leukemia (ALL), value of these treatments are limited by development of chemoresistance.
Gabriel O. Rodríguez‐Vázquez +4 more
openaire +1 more source
Journal of Clinical Oncology, 2022
5516 Background: Ovarian cancer is globally the second most common cause of death among women with gynecologic malignancies. Despite high initial response rates, the overall prognosis of this patient population remains poor. The majority of advanced ovarian cancers will become platinum resistant defined by recurrence within six months after ...
Alaa Embaby +12 more
openaire +1 more source
5516 Background: Ovarian cancer is globally the second most common cause of death among women with gynecologic malignancies. Despite high initial response rates, the overall prognosis of this patient population remains poor. The majority of advanced ovarian cancers will become platinum resistant defined by recurrence within six months after ...
Alaa Embaby +12 more
openaire +1 more source
Single-agent Adavosertib Shows Anticancer Effects Against Colorectal Cancer Cells
Anticancer ResearchColorectal cancer (CRC) is the third most common malignancy and the second most common cause of cancer-related deaths worldwide. Adavosertib (AZD1775), a small molecule inhibitor of WEE1 kinase, abrogates G2/M cell cycle arrest and induces double-stranded DNA breaks.
Mai Ly Thi, Nguyen +13 more
openaire +2 more sources
Molecular Cancer Therapeutics, 2019
Abstract Background: Small cell lung cancer (SCLC) is a highly aggressive type of neuroendocrine tumor with a low survival rate, signifying an unmet medical need. Although PARP inhibitors (PARPis) display single-agent anticancer activity in SCLC, the underlying biology is poorly understood.
Vinayak Palve +12 more
openaire +1 more source
Abstract Background: Small cell lung cancer (SCLC) is a highly aggressive type of neuroendocrine tumor with a low survival rate, signifying an unmet medical need. Although PARP inhibitors (PARPis) display single-agent anticancer activity in SCLC, the underlying biology is poorly understood.
Vinayak Palve +12 more
openaire +1 more source
Cancer Research, 2019
Abstract Background: Adavosertib is a highly selective inhibitor of Wee1, a crucial regulator of intra-S and G2/M cell cycle checkpoints. This Phase Ib study (NCT02610075) investigated dosing and schedule for adavosertib monotherapy and determined the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) in patients (pts ...
Gerald S. Falchook +8 more
openaire +1 more source
Abstract Background: Adavosertib is a highly selective inhibitor of Wee1, a crucial regulator of intra-S and G2/M cell cycle checkpoints. This Phase Ib study (NCT02610075) investigated dosing and schedule for adavosertib monotherapy and determined the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) in patients (pts ...
Gerald S. Falchook +8 more
openaire +1 more source
Aims: Adavosertib, a WEE1 inhibitor, has been studied for safety and efficacy as monotherapy and in combination therapy. The phase 2b ADAGIO trial evaluated adavosertib monotherapy for uterine serous carcinoma with a recommended dose of 300 mg dosing on days 1 to 5 and days 8 to 12 of 21‑day cycle.
Shankar Lanke +12 more
openaire +1 more source
Shankar Lanke +12 more
openaire +1 more source